2025 SOA Health Meeting: Session 5B: The Evolving World of Biosimilars -06.24.25- Recording

The first biosimilar drug approved in the United States was approved by the Federal Drug Administration (FDA) 10 years ago. Since that time (as of December 2024), 64 biosimilars for 18 reference products have been approved by the FDA. Historically, adoption rates for biosimilars have been relatively low for a variety of reasons. However, the recent launch of biosimilars for several blockbuster drugs have prompted payers to reevaluate their biosimilar strategy.
This session will explore the differences between biosimilars and generics by reviewing approval pathways and interchangeability guidelines. In addition, this session will review the current and future biosimilar landscape, adoption rates, and potential pricing strategies.